<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04012502</url>
  </required_header>
  <id_info>
    <org_study_id>2019-OR001</org_study_id>
    <nct_id>NCT04012502</nct_id>
  </id_info>
  <brief_title>De-escalation Protocols in HPV-related Oropharyngeal Carcinoma in Chinese Populations</brief_title>
  <official_title>De-escalation of Chemoradiotherapy Density in HPV-related Oropharyngeal Carcinoma in Chinese Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human papillomavirus (HPV)-related oropharyngeal carcinoma are exquisitely radiosensitive.
      Several studies attempted to reduce the toxicities of treatments through reduced-dose
      radiation and showed promising results, but all data were collected from non-Chinese areas.
      Like nasopharyngeal carcinoma, oropharyngeal carcinoma may have different biological behavior
      and relationship with HPV infection. So the investigators studied whether toxicities reducing
      treatment with reduced radiation dose and omitted concurrent chemotherapy after good response
      to induction chemotherapy would maintain survival outcomes while improving tolerability for
      patients with HPV-positive oropharyngeal carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>2 year</time_frame>
    <description>Progression Free Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>2 year</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">83</enrollment>
  <condition>Oropharyngeal Carcinoma</condition>
  <condition>De-escalation</condition>
  <arm_group>
    <arm_group_label>conventional treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toxicities reduced treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Toxicities reduced treatment</intervention_name>
    <description>Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)</description>
    <arm_group_label>Toxicities reduced treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>conventional treatment</intervention_name>
    <description>Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)</description>
    <arm_group_label>conventional treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological diagnosis of squamous cell carcinoma of oropharynx with IHC p16 positive
             or PCR HPV16 positive

          -  T1-2/N1-3M0（except T1N1M0 and single LN＜3cm）or T3-4N0-3M0 according to UICC/AJCC 8th
             staging system

          -  Age ≥18

          -  No prior anti-tumor treatment

          -  Karnofsky Performance Score (KPS)≥70

          -  Adequate blood supply

          -  Informed consent obtained

        Exclusion Criteria:

          -  cannot take contrast-MRI imaging

          -  Pregnant

          -  Combined with other malignant tumor (except basal cell carcinoma of skin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chaosu Hu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University Shanghai cancer centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tingting xu, MD</last_name>
    <phone>+8618017312903</phone>
    <email>dr_tingtingxu@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>xueguan Lu, MD</last_name>
    <phone>+8618121299382</phone>
    <email>luxueguan@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan Universtiy Shanghai Cancer Centre</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tingting Xu, MD</last_name>
      <phone>+8618017312903</phone>
      <email>dr_tingtingxu@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xueguan Lu, MD</last_name>
      <phone>+8618121299382</phone>
      <email>luxueguan@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 4, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Chaosu Hu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

